Plasma biomarkers for Alzheimer’s disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio (p-tau217/Aβ_42) with regulatory-authorized cerebrospinal fluid (CSF) biomarkers (Aβ_42/Aβ_40 and p-tau181/Aβ_42) for identifying AD pathology (Aβ-PET visual read) across a memory clinic ( n = 129), a primary care ( n = 220) and a research cohort ( n = 165). Regulatory-authorized cutoffs were used for the plasma and CSF biomarkers. Plasma biomarkers identified Aβ pathology with areas under the curve between 0.90 and 0.96. Using one cutoff, plasma p-tau217 (83–91%) and p-tau217/Aβ_42 (83–92%) had comparable accuracies to CSF (88–90%) across all cohorts (all P ≥ 0.05). With a two-cutoff approach, plasma p-tau217 (90–97%) remained comparable to CSF (91%) in the clinical cohorts (all P _adj ≥ 0.12). Results with cohort-derived cutoffs are also provided. In conclusion, regulatory-authorized plasma p-tau217 and p-tau217/Aβ_42 demonstrated performance comparable to regulatory-authorized CSF tests for detecting Aβ pathology in symptomatic individuals. Blood tests for Alzheimer’s disease, including regulatory authorized p-tau217 and p-tau217/AB_42, are accessible and cost-effective diagnostic tools. This study shows that they perform similarly to authorized cerebrospinal fluid tests in detecting Alzheimer’s disease pathology in patients.
Warmenhoven, et al. “Comparing plasma p-tau217 and plasma p-tau217/Aβ_42 with CSF biomarkers for assessing Alzheimer’s disease pathology.” Nature Aging, 2026. doi:10.1038/s43587-026-01259-z.
@article{Warmenhoven2026,
title = {Comparing plasma p-tau217 and plasma p-tau217/Aβ\_42 with CSF biomarkers for assessing Alzheimer’s disease pathology},
author = {Warmenhoven and Noëlle and Binette and Pichet, Alexa and Collij and E., Lyduine and Janelidze and Shorena and Mattsson-Carlgren and Niklas and Tideman and Pontus and Smith and Ruben and Strandberg and Olof and Ashton and J., Nicholas and Zetterberg and Henrik and Stomrud and Erik and Salvadó and Gemma and Hansson and Oskar and Palmqvist and Sebastian and Initiative, Alzheimer’s Disease Neuroimaging},
journal = {Nature Aging},
year = {2026},
doi = {10.1038/s43587-026-01259-z},
url = {https://www.nature.com/articles/s43587-026-01259-z}
}
Extreme longevity is accompanied by cardiac molecular remodelling, yet the basis of sex-associated adaptation during late-life aging remains incompletely understood. Here, we performed cardiac proteomic and multi-compartment metabolomic...
Aging natural killer (NK) cells might retain their killing machinery yet struggle to deploy it. Liu and colleagues now link this defect to retinoid-associated lipid remodeling, and show that inhibiting fatty acyl chain elongation...
Natural products derived from traditional medicines are valuable sources of potential geroprotective compounds; however, their translation into therapeutic candidates is limited by chemical complexity, polypharmacology, limited...